Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL
- PMID: 21994427
- PMCID: PMC3220857
- DOI: 10.2337/dc11-0685
Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL
Abstract
Objective: Using a mouse model for human-like lipoprotein metabolism, we observed previously that reduction of the hepatic triglyceride (TG) content resulted in a decrease in plasma cholesteryl ester transfer protein (CETP) and an increase in HDL levels. The aim of the current study was to investigate the effects of prolonged caloric restriction in obese patients with type 2 diabetes mellitus, resulting in a major reduction in hepatic TG content, on plasma CETP and HDL levels.
Research design and methods: We studied 27 obese (BMI: 37.2 ± 0.9 kg/m(2)) insulin-dependent patients with type 2 diabetes mellitus (14 men and 13 women, aged 55 ± 2 years) who received a 16-week very low calorie diet (VLCD). At baseline and after a 16-week VLCD, plasma lipids, lipoproteins, and CETP were measured. Furthermore, functionality of HDL with respect to inducing cholesterol efflux from human monocyte cells (THP-1) was determined.
Results: A 16-week VLCD markedly decreased plasma CETP concentration (-18%; P < 0.01) and increased plasma apolipoprotein (apo)AI levels (+16%; P < 0.05), without significantly affecting plasma HDL-cholesterol and HDL-phospholipids. Although a VLCD results in HDL that is less lipidated, the functionality of HDL with respect to inducing cholesterol efflux in vitro was unchanged.
Conclusions: The marked decrease in hepatic TG content induced by a 16-week VLCD is accompanied by a decrease in plasma CETP concentration and an increase in apoAI levels, without improving the cholesterol efflux properties of HDL in vitro.
Figures

Similar articles
-
Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.Eur J Clin Invest. 2003 Dec;33(12):1051-69. doi: 10.1111/j.1365-2362.2003.01263.x. Eur J Clin Invest. 2003. PMID: 14636288 Review.
-
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.Diabetes Care. 2010 Jul;33(7):1625-8. doi: 10.2337/dc09-1935. Epub 2010 Feb 11. Diabetes Care. 2010. PMID: 20150294 Free PMC article. Clinical Trial.
-
Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis.Circ Res. 2024 Jul 5;135(2):335-349. doi: 10.1161/CIRCRESAHA.123.323100. Epub 2024 Jun 3. Circ Res. 2024. PMID: 38828596 Free PMC article.
-
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10. Arterioscler Thromb Vasc Biol. 2016. PMID: 26966279 Free PMC article. Clinical Trial.
-
Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.Clin Lab. 2003;49(11-12):601-13. Clin Lab. 2003. PMID: 14651331 Review.
Cited by
-
The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease.Antioxidants (Basel). 2022 Nov 29;11(12):2363. doi: 10.3390/antiox11122363. Antioxidants (Basel). 2022. PMID: 36552571 Free PMC article.
-
Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome: A randomized trial.Cell Rep Med. 2022 Oct 18;3(10):100777. doi: 10.1016/j.xcrm.2022.100777. Epub 2022 Oct 10. Cell Rep Med. 2022. PMID: 36220069 Free PMC article. Clinical Trial.
-
Effects of short-term nutritional interventions on right ventricular function in healthy men.PLoS One. 2013 Sep 23;8(9):e76406. doi: 10.1371/journal.pone.0076406. eCollection 2013. PLoS One. 2013. PMID: 24086738 Free PMC article.
-
Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.Sci Rep. 2019 Jul 10;9(1):9996. doi: 10.1038/s41598-019-45593-2. Sci Rep. 2019. PMID: 31292457 Free PMC article. Clinical Trial.
-
The long-term coronary heart disease risk of previously obese patients with type 2 diabetes mellitus.BMC Endocr Disord. 2013 Oct 3;13:38. doi: 10.1186/1472-6823-13-38. BMC Endocr Disord. 2013. PMID: 24090279 Free PMC article.
References
-
- Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235–240 - PubMed
-
- Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947–1953 - PubMed
-
- Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906–E916 - PubMed
-
- Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854–858 - PubMed
-
- Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002;2:210–215 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous